Zobrazeno 1 - 10
of 91
pro vyhledávání: '"C. Bresson-Vautrin"'
Autor:
Thomas Crepin, Jamal Bamoulid, Cécile Courivaud, Didier Ducloux, Jean-Marc Chalopin, Maria Yannaraki, C. Bresson-Vautrin, Nadège Devillard, Bérengère Vivet, Amir Kazory, Hélène Philippot, Caroline Roubiou
Publikováno v:
BMC Nephrology
BMC Nephrology, Vol 20, Iss 1, Pp 1-9 (2019)
BMC Nephrology, Vol 20, Iss 1, Pp 1-9 (2019)
BackgroundAcute kidney injury (AKI) is still characterized by a high mortality rate. While most patients with AKI are admitted in conventional medical units, current available data are still obtained from studies designed for patients admitted in int
Autor:
Cécile Courivaud, C. Bresson-Vautrin, E. Delabrousse, C. Roubiou, Jean-Marc Chalopin, Didier Ducloux
Publikováno v:
Clinical Kidney Journal
Background. For many nephrologists, patients with polycystic kidney disease (PKD) have an increased risk of complications and technique failure on peritoneal dialysis (PD) due to enlarged kidneys. The literature showed that PD can be as good a therap
Autor:
Didier Ducloux, Jérome Coutet, Gérard Motte, Jean-Marc Chalopin, Bruno Challier, C. Bresson-Vautrin, Jean-Michel Rebibou, Bernard Thalamy, Amir Kazory
Publikováno v:
Transplantation. 77:1029-1033
Background Antithymocyte globulin (ATG) preparations are frequently used as induction treatment in renal transplantation, but little is known about the clinical equivalence of these different agents. We performed a retrospective, single-center study
Publikováno v:
Kidney International. 62(4):1417-1422
C-reactive protein and cardiovascular disease in peritoneal dialysis patients.BackgroundElevated plasma concentrations of C-reactive protein (CRP) is a risk factor for cardiovascular disease (CVD) in the general population and in hemodialysis patient
Autor:
E. Racadot, E. Pellet, D Fellmann, V. Fournier, C. Bresson-Vautrin, Jean-Michel Rebibou, Jean-Marc Chalopin, Didier Ducloux
Publikováno v:
Transplantation. 67:90-93
Background. The prevalence and clinical significance of antiphospholipid antibodies (APAs) have not been extensively studied in non-systemic lupus erythematosus (non-SLE) renal transplant recipients. Methods. To further define the prevalence and clin
Autor:
Christophe Ruedin, Jean-Marc Chalopin, Roger Gibey, Didier Ducloux, P Vautrin, C. Bresson-Vautrin, Jean-Michel Rebibou
Publikováno v:
Nephrology Dialysis Transplantation. 13:2890-2893
BACKGROUND Previous studies have demonstrated that hyperhomocyst(e)inaemia is present in patients with impaired renal function and is correlated with cardiovascular disease. Because conflicting data are available on the prevalence, determinants, and
Publikováno v:
Transplant International. 11:312-315
Post-transplant erythrosis (PTE) develops in 9%-22% of all renal transplant recipients. Defined as a persistently elevated hematocrit (0.51), it occurs most commonly during the first 2 years post-transplantation in hypertensive males with excellent a
Publikováno v:
Nephrology Dialysis Transplantation. 12:2389-2392
Few data are available about the muscle status in renal transplant recipients. Moreover, the list of myotoxic drugs is growing longer and some of them are likely to be prescribed in renal transplant patients. These conditions may act as confounding f
Autor:
Cécile Courivaud, C. Bresson-Vautrin, Didier Ducloux, Jean-Marc Chalopin, Raymond Azar, Amir Kazory, Thomas Crepin
Publikováno v:
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 34(1)
Background Previous small studies have reported favorable results of peritoneal dialysis (PD) in the setting of chronic refractory heart failure (CRHF). We evaluated the impact of PD in a larger cohort of patients with CHRF where end-stage renal dise
Autor:
Jean-Marc Chalopin, Thierry Lobbedez, P. Fort, C. Bresson-Vautrin, Cécile Courivaud, Jean-Philippe Ryckelynck, Didier Ducloux
Publikováno v:
Néphrologie & Thérapeutique. 10:304-305
Introduction Une antibiotherapie administree par voie intra-peritoneale est recommandee dans la prise en charge des infections peritoneales (IP) en dialyse peritoneale (DP). Neanmoins, l’utilisation de la voie systemique (per os, IV) reste a ce jou